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Abstract 
Composite scaffolds formed from polymers and bioglasses have been widely explored for 
applications in regenerative medicine as they have suitable organic/inorganic structures and 
properties similar to human hard tissue. Yet, these materials have only been used for non-load-bearing 
or low load-bearing purposes as they have limited mechanical strength while research is focused on 
improving their properties. One method of improving mechanical strength is by covalently bonding 
the organic and inorganic phases. This has been successfully achieved in Class ll hybrids which have 
covalent bonding between polymers and bioglasses. As well as improving mechanical strength, the 
chemical connection of the two phases results in simultaneous degradation. The currently available 
composite scaffolds use collagen for the polymer phase which can cause allergic reactions and 
transmit pathogens. An alternative natural polymer is chitosan which has been used to create 
scaffolds with bioglass avoiding the issues arising from collagen. Additionally, using cross-linking 
agents has been shown to strengthen chitosan hydrogels improving their mechanical properties. A 
promising natural cross-linker is genipin which has lower toxicity than other cross-linking agents while 
producing hydrogels with improved mechanical properties compared to pure chitosan. In this paper 
we offer an overview of requirements, structures and currently available composite scaffolds for 
tissue engineering applications. We discuss the limitations of the currently available materials and 
consider the potential of covalently bonded hybrids particularly in relation to chitosan-based materials 
and the added benefits of genipin cross-linking. 
1. Introduction - The need for synthetic bone replacements and application of polymer/ceramic 
materials 
Tissue engineering is a promising field of research which aims to replace and repair damaged 
or diseased tissues and organs with substitutes made of synthetic or natural compounds. It involves 
prostheses and parts with the ability to regenerate tissues, as well as vehicles for the delivery of drugs, 
cells or biomolecules, and the coating of non-biological apparatus (e.g. stents) with bioactive materials 
to enable interaction with cells [1]. According to data from 2016, the biomaterial market was 
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estimated to be $70.90 billion and is expected to reach $149.17 billion by 2021 [2]. Due to injury, 
disease, surgical procedures, increasing life span and a rising population, orthopaedic implants are in 
particular demand [3]. 
After blood, bone transplantation is the second most common tissue transplantation with 
over 2 million bone graft operations taking place every year worldwide [4, 5]. Autografts, grafting 
tissue from the same donor from one bone tissue to another, continue to be the gold standard. They 
are used in about 60% of all bone graft procedures due to their ability to promote bone formation and 
induce bone tissue growth without causing an immune response [5]. Other options include allografts 
(tissue from the same species but not genetically identical), used in about 35% of bone graft 
procedures, and xenografts (when the donor is another species) [5]. However, certain issues 
associated with these natural materials can arise: a lack of supply of suitable tissue for large defects 
when using autografts; donor site complications (most commonly persistent pain) and a negative 
immune response of the patient that can occur when using allografts or xenografts [3, 5, 6]. For these 
reasons, synthetic materials have been widely investigated as alternatives [1, 3, 6]. 
In order to replace natural tissue, synthetic materials need to have similar properties to native 
tissue [7]. Since its beginning 30 years ago, tissue engineering has developed greatly and there are 
numerous commercially available synthetic bone graft substitutes [5, 8-13]. These are composites of 
mainly collagen and calcium phosphate, mostly used for dental applications and for repairing joints 
and broken bones [5, 8, 9, 11-13]. These composites have a composition similar to natural bone tissue 
(composed of an inorganic phase (hydroxyapatite) and an organic phase (collagen)). They overcome 
the problems linked to auto- and allografts mentioned previously, and  have the potential to achieve 
enhanced mechanical properties combining the strength of ceramics with the flexibility of polymers 
[5]. Furthermore, producing composites with natural polymers has the added advantages of 
biocompatibility and the ability to stimulate cells, enhancing adhesion and differentiation. Natural 
polymers such as gelatin and chitosan are mainly degraded by enzymes. In chitosan, the enzymes 
gradually hydrolyse the bonds between the glucosamine and N-acetyl-glucosamine units present in 
the chitosan structure [14]. This is a promising feature compared to synthetic polymers like polyesters 
(US Food and Drug Administration (FDA) approved polymers widely used for sutures, drug delivery, 
vascular grafts, skin replacement, dental and orthopaedic implants and cartilage repair) which 
degrade rapidly once degradation begins [4, 15]. The combinations of ceramics and natural polymer 
materials reported so far have been limited to non-load-bearing and low load-bearing applications. 
However, due to their properties, such as bone-like architecture, ability to stimulate and enable new 
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bone and blood vessel formation as well as encouraging results in clinical applications, 
ceramic/polymer composites continue to be studied [5, 7-9, 16-20]. 
2. Scaffolds and their properties 
One way to employ ceramic/polymer composite materials is to design them into scaffolds. 
Scaffold materials are porous and degradable structures that should provide mechanical support to 
bone defects, and allow cells to proliferate and differentiate [17, 21]. In order to be successful, 
scaffolds must fulfil numerous requirements:  
1) Biocompatibility – this essential property for biomaterials is defined as the ability of a material 
to support normal cellular activity without causing local or systemic damage to the 
surrounding living tissue [17]. Ideally, the scaffold should also be osteoconductive (allow bone 
growth on its surface and in the pores) and osteoinductive (stimulate non-differentiated cells 
to develop into bone-forming cells) [4, 5, 17, 22]. The porous structure of the scaffolds should 
allow formation of new blood vessels [4, 17]. 
2) Bioactivity – this represents the ability of the scaffold’s surface to form an apatite layer (bone-
like layer of hydroxyapatite) through which the scaffold will bond to the native bone tissue 
when implanted into the body. A test method first developed by Kokubo for bioactive glass 
ceramics employs a simulated body fluid (SBF) which has a composition similar to human 
blood plasma [23]. This test can be used to detect apatite formation on the surface of a 
composite material and predict apatite formation in vivo (ISO 23317:2014 ). 
3) Mechanical properties – it is important that the mechanical properties of the synthetic 
material match those of the surrounding tissue, along with the load transfer between the 
implant and the tissue [4, 5, 17]. Properties of cancellous and cortical bone are given in Table 
1. Load-bearing materials should have mechanical properties within the range of properties 
of cortical bone (low load-bearing materials exhibit mechanical properties near the lower limit 
of cortical bone and high load-bearing materials close to the upper limit of the cortical bone 
range) [24]. 
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Table 1. Mechanical properties of cancellous and cortical bone and synthetic scaffolds [5, 17, 25-27] 
Property Cancellous bone Cortical bone 
PLGA/45S5 
Bioglass scaffold 
Chitosan/bioglass 
scaffold 
Compressive strength 2 – 20 MPa 100 - 200 MPa 0.42 MPa 7.68 MPa 
Compressive modulus 0.1- 2 GPa 15 - 20 GPa 51 MPa 0.46 GPa 
Tensile strength 10  - 20 MPa 90 – 130 MPa Not reported 3.11 MPa 
Young’s modulus 0.1- 4.5 GPa 17 – 24 GPa Not reported 0.196 GPa 
Fracture toughness 0.1-0.8 MPa m1/2 2-12 MPa m1/2 Not reported 0.24 MPa m1/2 
 
So far, synthetic scaffolds are not yet achieving the higher end of the desired properties, which is why 
their applications have been limited to low load-bearing conditions such as bone fillers and 
maxillofacial reconstructive procedures [5]. 
4) Porosity - scaffolds with pore sizes of 20-1500 µm have been reported in bone tissue 
engineering [28]. According to in vitro and in vivo studies, scaffolds are required to possess 
open interconnected pores with at least 100 µm in diameter in order to enable successful 
transport of food and oxygen for the cells and to allow removal of waste products [5, 17, 28-
30]. In vivo studies showed that only pores larger than 100 µm enable healthy mineralized 
bone formation, while smaller size pores (75 – 100 µm) lead to the formation of unmineralized 
bone tissue  which causes disease and disorders (e.g. pain, muscle weakness and fracturing of 
the bone) [30]. At the same time, when the pores had diameters in the region of 10 - 75 µm, 
formation of fibrous (scar) tissue, was reported [30]. Fibrous tissue only connects with the 
surrounding tissue but does not possess mechanical and other characteristics of bone tissue, 
which also manifests as disease and disorder. Furthermore, several reports suggest that the 
optimum pore size is 200 – 350 µm, and that both micro- and macroporosity is needed to 
enhance bone ingrowth [17, 28, 30]. Although greater porosity, is beneficial for cells to 
proliferate and differentiate it reduces the mechanical strength of the scaffold [30]. It is worth 
noting that healthy cancellous has a porosity of 50-90% with pore sizes of 300 - 600 µm, and 
cortical bone has a porosity of 3-12% with pore sizes of 10 – 50 µm in diameter [30, 31]. These 
values, as well as the strength and modulus of the bone, vary depending on race, age and sex 
[5, 30-32]. Vitoss™ (Orthovita), a collagen I/β-tricalcium phosphate composite scaffold used 
clinically, has 90% porosity with pores ranging from 1 to 900 µm which encompasses the range 
of healthy cancellous bone [12]. 
Despite the necessity for macroporosity, it has been demonstrated that micropores also play 
an important role for osteogenesis [33]. The apatite layer, which forms on the surface of bioactive 
implants after immersion in a simulated environment or in vivo is important for bone growth because 
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it initiates cell adhesion, proliferation and differentiation [34]. This apatite layer can also serve as a 
conductor for bone growth [34]. Since micropores (< 20 µm) enlarge the surface area, it is easier for 
the apatite layer to be formed (due to easier ion exchange by dissolution and precipitation processes), 
and is easier for proteins to attach to the surface of the material, leading to enhanced cell activity [29, 
33]. It is worth reiterating that macroporosity has a bigger role in affecting the mechanical properties 
of scaffolds than microporosity [29]. The reason for this is that structures with large pores are only 
connected via necks/bridges which offer weaker support than denser structures. For example, in 45S5 
Bioglass scaffolds with 60% porosity reducing the pore size from 700 µm to 400 µm increased 
compressive strength from 3.5 to 6.7 MPa [35]. 
The geometry of the pores present in the scaffold is shown to dictate the pattern of bone 
formation: discontinuous bone ingrowth was found in specimens containing controlled, network-
structured pores, while continuous growth was seen in scaffolds with randomly distributed pores. It 
was concluded that discontinuous bone ingrowth tends to result in faster filling of the scaffold when 
compared to continuous growth; however, the overall amount of bone formation remained 
unaffected [36]. Furthermore, when the samples contained microporous walls as well as a systematic, 
organized architecture, both types of bone ingrowth were detected (continuous and discontinuous). 
These findings suggest that by controlling the pore size of scaffolds, and most importantly pore 
architecture, it is possible to direct the pattern, discontinuous or continuous, as well as time of bone 
growth [36]. 
5) Biodegradability - scaffolds are expected to degrade over time to make room for the new 
tissue to grow. After implantation, scaffolds should have a similar strength to the host tissue 
and degrade over time with a controlled rate, depending on the application [4, 5, 17]. 
Reported degradation times vary from 3 to 6 months for scaffolds used in cranio-maxillofacial 
(skull, face, jaws, mouth) procedures to approximately 9 months or more for those used in 
spinal fusion [17]. For example, RegenOss® (JRI Orthopaedics), a clinically used collagen 
l/hydroxyapatite scaffold, degrades between 6 and 12 months after implantation [12]. Ideally, 
products formed by degradation of the implanted material should be non-toxic. 
6) Porosity and degradation rate interplay – these two factors need to be tuned, that is if the 
degradation rate of the material is high, initial porosity needs to be low otherwise the scaffold 
resorbs too fast disabling the mechanical support and affecting the growth of the new tissue 
[30]. Conversely, materials that degrade at a low rate can be highly porous to bring the 
degradation rate to an optimal level [30]. Additionally, higher specific surface area accelerates 
the degradation rate. The general consensus regarding the porosity needed for scaffold 
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application is that high porosity (over 80%) and bigger pores (>300 µm) favour new bone 
ingrowth, while mechanical strength dictates the limits of porosity and pore size [30, 37].  
Scaffolds made of ceramics, polymers and combinations of these materials have been studied, 
and some have been used for clinical applications, such as blood vessels, drug and biomolecules 
delivery, cartilage, bone, and dental regeneration [5, 7, 8, 11-13, 17, 20, 21, 38-48]. Ceramic scaffolds 
are strong but brittle, while polymer scaffolds are mostly weak and ductile [5, 7, 8, 17, 20]. Ceramics, 
particularly bioglasses, in combination with polymers are being pursued with the aim of producing a 
composite biomaterial which will overcome the drawbacks of the individual materials, while 
resembling natural bone structure consisting of both inorganic and organic components [4, 5]. Yet, 
fulfilling all the requirements for an ideal scaffold, including high porosity, biocompatibility, 
biodegradability and suitable mechanical properties, while maintaining all the other parameters 
remains a challenge [17]. 
 
3. Bioglasses 
Ceramics, and bioglasses among them, are of interest for tissue engineering applications on 
their own but also as a way to improve polymer properties (in particular bioactivity and mechanical 
strength) via the formation of composites which would suit biomedical applications. The first bioglass 
(45S5 Bioglass) was discovered by Larry Hench in 1969, and it was the first material which formed a 
good bond with bone [4]. 45S5 Bioglass has shown excellent biocompatibility and bioactivity in vivo as 
the layer of hydroxyapatite is formed on the surface [25]. 45S5 Bioglass also stimulates new bone 
formation with superior osteoinductive properties compared to hydroxyapatite and promotes 
angiogenesis (formation of blood vessels) [21, 49]. Dense 45S5 Bioglass is reported to have a 
compressive strength of 500 MPa, tensile strength 42 MPa, Young’s modulus 35 GPa and fracture 
toughness of 0.7-1.1 MPa m1/2 [26]. 
45S5 Bioglass was then followed by the development of other bioglass and bioglass-ceramic 
materials, such as 13-93 and apatite-wollastonite (A-W) glass-ceramic (Table 2) [4]. All bioglasses 
shown in Table 2 form a bond with bone, but the length of the bonding process, strength and thickness 
of the formed bond, as well as the mechanism of bond formation vary among different compositions, 
which in turn defines their application [50]. By modifying the composition, bioglasses can be designed 
to degrade at a controlled rate that matches the development of new bone tissue, without any toxic 
effects [25]. According to M. Pilia et al. [51] commonly used bioglasses have compressive strength 
800-1200 MPa and Young’s modulus 40-140 GPa but fracture toughness of around 2 MPa m1/2. 
Furthermore, because many bioglasses have proven to have considerable antibacterial properties 
caused by cation leaching and a consequent rise in pH it makes them particularly useful in clinical 
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applications [4, 52-56]. For example, 45S5 Bioglass has been shown to kill Enterococcus Faecalis which 
is associated with failed root canal treatment while S53P4 has been shown to kill pathogens associated 
with enamel caries, root caries and periodontitis [4, 52-56].  
Bioglass scaffolds have a number of excellent properties such as biocompatibility, bioactivity, 
degradability over time, and interconnected porosity suitable for bone ingrowth [4, 57, 58]. They can 
also be produced to have similar compressive strength to that of cancellous bone. For example, 
scaffolds made from 13-93 bioglass have been reported to have a compressive strength of 11 MPa, 
and an elastic modulus of 3 GPa (85% porosity with pore size of 100–500 μm) [26]. Generally, the 
literature shows that the compressive strength for bioglass scaffolds is in the range of 0.2-150 MPa 
(porosity 30-95%) and fracture toughness is 0.5-1 MPa m1/2 which is low for load-bearing applications 
[59]. However, these scaffolds are not appropriate for applications that require flexibility or fatigue 
resistance as they are brittle [4]. Nevertheless, since bioglass is a material with high mechanical 
strength, it has its uses in combination with other materials where it serves as reinforcement, 
improving the properties of polymers and particularly to capitalise on the properties of the natural 
polymer chitosan [25]. Additionally, according to Jones [4] as well as Tajbakhsh and Hajiali [60], 
bioglasses can slow down the degradation of some polymers by releasing alkali metal ions that reduce 
the acidic pH produced by polymer degradation thereby acting as a buffer. The degradation rate is 
dependent on the percentage of bioglass in the composite [4, 60]. It has been suggested that the 
strong, covalent bond between the polymer and bioglass produces simultaneous degradation of the 
composite (section 5.1). However, it should be mentioned that other studies show that bioglass also 
increases swelling and degradation by making the composite more hydrophilic [4]. 
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Table 2. Examples of bioglass compositions [50, 61, 62]  
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4. Polymer/bioglass scaffolds 
4.1 Types of polymer/bioglass scaffolds 
In the quest to capitalise on the advantageous properties of polymers and bioglasses, there 
have been a number of successfully designed polymer/bioglass scaffolds. Based on their physical 
structure (appearance), the composite polymer/bioglass scaffolds reported so far can be classified in 
the following groups: 
 
1) Foam/sponge-like structures (scaffolds) (Figure 1). A variety of methods have been used to 
develop these scaffolds including freeze-drying, foam replica, phase separation, particle 
leaching, dip- and slurry-coating and rapid prototyping [63-67]. Also, a large number of 
different polymers, both synthetic and natural, as well as different compositions of bioglasses 
have been used for this type of scaffold in order to obtain different designs [4, 16, 65, 68-78]. 
In general, scaffolds can be composed in two ways: a) they can consist of a matrix and a 
coating, where polymer foam can be coated with a bioglass slurry or a bioglass scaffold can 
be coated with polymer solution; or b) they can be formed as a monolith structure from 
bioglass particles dispersed in polymer solution [25, 64, 66, 67, 79]. 
 
 
 
Figure 1: Example of a foam-like composite material reproduced with permission from [80]. 
Copyright 2011. The Royal Society of Chemistry 
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2) Fibre composites (Figure 2). These are most widely synthesised via an electrospinning 
method, where materials can be mixed together prior to electrospinning or polymer fibres 
can be immersed in a bioglass slurry to coat the fibres [81-86]. A high surface area and high 
porosity make fibre scaffolds attractive for bone tissue applications, although reported 
mechanical properties are usually low or not stated [82, 84, 87]. Polyhydroxybutyrate 
(PHB)/poly(ε-caprolactone) (PCL)/58S bioglass (60 wt% SiO2, 36 wt% CaO and 4 wt% P2O5) 
fibre scaffolds designed by Ding et al. exhibited a tensile strength of approximately 2 MPa and 
Young’s modulus in the region of 67-87 MPa [88]. In another study by Foroughi et al, 
PHB/chitosan/45S5 Bioglass scaffolds showed a tensile strength in the region of 3 MPa and 
Young’s modulus of 0.2 GPa (see Table 1 for comparison) [89]. 
 
 
Figure 2. Fibre scaffold adapted with permission from [84]. Copyright 2013. Wiley Periodicals, Inc. 
 
3) Microsphere scaffolds. Microspheres are mainly composed of polymers, but bioglass or other 
ceramics can be added to enhance mechanical strength and bioactivity of the materials, and 
control the degradation of the polymer. Microspheres can be fused together to form a 3D 
scaffold (Figure 3) [90-93]. This can be achieved by heating, using a solvent (e.g. methylene 
chloride and acetone), which is a milder method compared to heating, or via particle 
agglomeration techniques. This type of composite scaffold has been used for gene therapy 
and drug delivery in the antibiotic treatment of infected bone. Prior to fusing, the spheres are 
loaded with drugs which are released gradually over time. While microspheres offer the ability 
to encapsulate and release biomolecules and drugs, scaffolds composed of fused 
microspheres also possess porosity and mechanical support for loading cells, a useful feature 
for bone regeneration applications. This method of producing polymer/bioglass scaffolds is 
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reported to give improved mechanical properties similar to cancellous bone (compressive 
strength 4-8 MPa and compressive modulus 0.1-0.3 GPa) (see Table 1 for comparison) [94]. 
 
 
Figure 3. Microsphere scaffolds adapted with permission from [91]. Copyright 2014. The Royal 
Society of Chemistry 
 
4) Bilayer or multilayer scaffolds. These scaffolds are designed for osteochondral applications 
which include both bone and cartilage tissue [11, 95, 96]. They consist of two or more layers; 
a bone-like layer (calcium phosphate material, polymer coated bioglass scaffold, or 
bioglass/polymer scaffold) and a cartilage layer (polymer material). The layered structure of 
the materials follows the natural architecture of a human osteochondral unit, where the bone-
like part is used to support bone formation, while the cartilage-like part is used for guiding the 
formation of cartilage. Some scaffolds have an intermediate layer which serves as a ‘glue’ 
between the bioglass and polymer layers, and is usually made from a polymer or a 
polymer/hydroxyapatite composite (Figure 4) [11, 95]. A promising example was developed 
by Boccaccini et al. in which polyamide short fibres were applied as an external cartilage-like 
layer, to imitate collagen fibres, on a gelatin coated 45S5 Bioglass scaffold (Figure 5) [97]. 
 
 
Figure 4. Multilayer composite scaffold made of polyvinyl alcohol (PVA) coated bioglass, 
polymeric (chitosan, alginate, gelatin or sucrose) and chitosan layers [95]. In this case, scaffolds 
were covered with polymeric solution by dipping and the chitosan membrane was fixed manually 
reproduced with permission from [95]. Copyright 2012. Elsevier B. V. 
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Figure 5: Bilayered gelatin coated 45S5 Bioglass scaffold with polyamide short fibres adapted 
with permission from [97]. Copyright 2015. Elsevier B. V. 
 
5) Cell-seeded scaffolds. Here, cells are integrated into the composite scaffolds [48, 98, 99]. The 
presence of cells in engineered materials is found to improve osteogenesis in vivo so these 
scaffolds can serve as skeletons for cell incorporation and mechanical support [11, 100]. 3D 
printing or other additive manufacturing methods can be used for scaffold synthesis [98]. 
Figure 6 describes two different approaches for integrating cells into 3D printed materials. In 
the first approach cells are added to the hydrogel solutions (precursor materials) which are 
used to print 3D scaffolds. The second approach prints a 3D scaffold and then seeds it with 
cells [98]. The main issue with the first approach is the difficulty in designing scaffolds with 
the exact shape and mechanical properties that are required, whereas in the second 
approach, surface modification is necessary in order for the cells to be attached to the scaffold 
properly which complicates the fabrication process. Cells can also be seeded onto scaffolds 
fabricated via other routes, such as particulate leaching, thermally induced phase separation 
(TIPS), and the sponge replica method [48, 99, 101]. Microsphere scaffolds can also be loaded 
with cells and/or drugs. [93]. 
While multi-layered scaffolds are appropriate for osteochondral regeneration, polymer coated 
sponge-like bioglass scaffolds and microsphere scaffolds are suggested for use in bone defects as 
these types of structures give better mechanical properties than fibre scaffolds or polymer sponge 
scaffolds with dispersed bioglass. Additionally, cell-seeding can improve cell attachment to 
implanted scaffolds and enhance bone formation. 
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Figure 6: Cell-seeded scaffolds adapted with permission from [98]. Copyright 2015. Springer 
Science+Business Media New York 
4.2 In vivo tested and commercially available polymer/bioglass composite scaffolds 
A number of studies have reported in vivo testing of polymer/ceramic composite scaffolds 
designed for haemostasis (to stop bleeding), blood vessels, the delivery of drugs and biomolecules, 
and cartilage and bone regeneration applications [5, 11, 47, 48, 82, 86, 101-109]. Some of the 
materials for osteochondral regeneration with a multi-layered type of structure are under clinical 
trials. They consist of a combination of polymers (to mimic cartilage) and ceramics (to mimic bone 
tissue). ChondroMimeticTM is a composite based on type I collagen, chondroitin-6-sulfate, and calcium 
phosphate. TruFitTM consists of poly(lactic-co-glycolic acid) (PLGA) and poly(glycolic acid) (PGA) fibers, 
and calcium sulphate. MaioRegen® is made of three layers: type I collagen, a mixture of type I collagen 
and hydroxyapatite (60:40 wt% respectively) and a mixture of type I collagen and hydroxyapatite 
(30:70 wt% respectively) [11]. The use of multi-layered materials leads to optimal integration of 
repaired tissue with the native tissue in preclinical trials which examined several features including 
structural characteristics, mechanical properties, reconstruction of the bone, cellularity, the amount 
of defect filling area and the presence of defects [110]. The use of the natural polymer collagen (in 
ChondroMimeticTM) was shown to have advantages over PLGA (in TruFitTM). ChondroMimeticTM had 
better scores (according to Seller’s scoring system for cartilage repair), rapid cell infiltration and bone 
matrix formation within the implanted materials, while TruFitTM had more bone defects in the form of 
cysts (bone cavities filled with fluid) [110]. The degradation of natural polymers is enzymatic with 
peptide and saccharide fragments being the products of degradation of collagen, which do not affect 
the local pH as they are naturally found in cartilage. On the other hand, degradation of PLGA leads to 
formation of acid oligomers (of lactic and glycolic acids) which have a detrimental effect on cells and 
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calcium phosphate formation leading to bone cysts. This was shown to induce a lack of integrity of the 
PLGA- materials with native tissue. Clinical reports of the multi-layered type of materials are 
contradictory and vary according to the study conducted [111-113]. Some studies report good follow-
up and success in patients with patients being able to return to sporting activities, experiencing relief 
of symptoms and magnetic resonance imaging (MRI) showing complete filling of the defect and 
integration of the graft [112, 113]. For example, an Olympic fencer was able to compete 17 months 
after the implantation surgery [114]. However, the literature also reports a high rate of failure 
(formation of fibrous tissue and need for reoperation) when the same materials were used in other 
patients [111, 112]. The opposing outcomes are dependent on the age and previous activity levels of 
the patient as well as the different defect sites treated. As the data for the aforementioned multi-
layered materials for cartilage repair does not give definitive answers on safety and efficiency in clinic, 
it suggests that novel materials (or improved existing materials) are needed. 
Some commercially available composite scaffolds for bone tissue applications which have a 
sponge-type structure are shown in Table 3 [5, 12, 115]. Lerner et al. [116] reported that Vitoss 
(Orthovita), a scaffold of β-tricalcium phosphate and type I collagen, has similar results to autografts 
in scoliosis surgery. Radiographs showed complete and continuous fusion of the bone in both cases, 
while the 4/20 patients who received autographs suffered from donor site pain. One of the most 
successful commercially available bone graft products in the USA is Healos (DePuy Orthopaedics) 
which is a scaffold made of a matrix of cross-linked collagen fibres coated with hydroxyapatite [13]. 
Healos is successful because it requires less time for preparation but gives similar clinical results to 
autographs while avoiding donor site complications [117]. One big drawback of most of the 
commercially available polymer/bioglass composite scaffolds (see Table 3) is they use collagen, which 
can cause allergic reactions with some patients (although not common) and transmit pathogens 
because the collagen comes mainly from porcine and bovine sources [5, 118]. 
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Table 3: Commercially available natural polymer/ceramic composite scaffolds [5, 12, 115] 
Product Composition and structure Recommended use 
Collagraft® (Zimmer) 
Collagen l fibres and 
hydroxyapatite/tricalcium 
phosphate porous granules 
Acute long bone fractures and 
traumatic osseous defects 
Collapat® ll (BioMet 
lnc.) 
Collagen l and hydroxyapatite 
(hydroxyapatite granules 
dispersed in collagen structure) 
Aseptic enclosed metaphyseal bone 
defects 
FormaGraft® (Maxigen 
Biotech Inc.0 
Collagen l and  
hydroxyapatite/β-tricalcium 
phosphate granules 
Bone void filler 
Integra Mozaik™ 
(Integra 
OrthoBiologics) 
Collagen l and β-tricalcium 
phosphate 
Bone void filler 
CopiOs® (Zimmer) 
Collagen l and calcium 
phosphate 
Bone void filler 
Biostite® (Vebas) 
Collagen l/chondroitin-6-sulfate 
and hydroxyapatite 
Filling of periodontal defects, pre-
prosthetic osseous reconstruction, 
maxillo-facial reconstructive 
surgery 
Bio-Oss Collagen® 
(Geistlich 
Biomaterials) 
Porcine collagen and 
hydroxyapatite granules 
Filling of periodontal defects, 
alveolar ridge 
TricOs T® (Baxter) 
Fibrin and  hydroxyapatite/β-
tricalcium phosphate  granules 
Bone void filler 
RegenOss® (JRI 
Orthopaedics) 
Collagen l fibres and Mg-
enriched hydroxyapatite nano-
crystals 
Long bone fractures, revision hip 
arthroplasty to fill acetabular 
defects and spinal fusion 
NanOss® Bioactive 3D 
(Pioneer surgical) 
Collagen and nano 
hydroxyapatite granules 
Bone void filler 
Vitoss™ (Orthovita) 
Collagen I and β-tricalcium 
phosphate 
Spinal and trauma surgery 
Healos® (DePuy 
Orthopaedics) 
Matrix of cross-linked collagen 
fibres coated with 
hydroxyapatite 
Spinal surgery 
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Even though products such as Healos and Vitoss have shown radiological and clinical results 
comparable to autografts, there are still some issues to be resolved such as the use of collagen, the 
need for further trials to determine clinical efficiency and insufficient mechanical properties for high 
load-bearing applications [5, 12, 117, 119]. The lack of high-load bearing applications of the developed 
polymer/ceramic scaffolds is because the bonding between the organic and inorganic phases in the 
current scaffolds is weak allowing the phases to degrade separately at different rates [4, 5]. This causes 
insufficient mechanical integrity resulting in inadequate mechanical properties [4]. Ultimately the 
scaffolds need better interfacial bonding between the polymer and bioglass phases to improve the 
mechanical properties.  
5. Ongoing research aiming to overcome existing problems 
5.1 Hybrids 
It has been shown that microporosity is needed for good adhesion and linkage between the 
ceramic and polymer phases, which in turn improves mechanical performance [120]. Good dispersion 
of the bioglass particles in the polymer matrix is crucial to avoid aggregation and the consequent 
decrease in strength. Hybrid materials have the potential for a more homogeneous structure as well 
as the advantage over traditional composites because the constituents are interacting on a molecular 
level. A hybrid is defined as a composite of an inorganic and an organic material, where properties of 
the hybrid differ from the individual properties of the two materials because of the interactions 
between them. Hybrid materials are classed depending on the types of interactions occurring at the 
interface. Class I hybrids have weak bonds such as electrostatic, van der Waals and hydrogen bonds. 
This can be achieved by sol-gel synthesis [4, 121]. When covalent bonds between polymer and bioglass 
are present, the materials are called Class II hybrids [4, 122]. These materials have the potential for 
good bioactivity, improved mechanical properties and controlled and congruent degradation (the 
composition remains the same during degradation) [4].  
Linkage can be achieved by using certain polymers with functional groups or by functionalization of 
the surface of either the bioglass or polymer before the sol-gel process [4, 123-130]. Silanes 
(glycidoxypropyltrimethoxysilane (GPTMS) and 3-aminopropyltriethoxysilane (APS)), hexamethylene 
diisocyanate (HMDI) and polyvinyl alcohol (PVA) are amongst the compounds used for developing 
Class l and Class II hybrid materials [123-130]. In a poly (L-lactide) (PLLA)/bioglass scaffold (with 
bioglass composition 4.6 wt% MgO, 44.7 wt% CaO, 34.0 wt% SiO2, 16.2 wt% P2O5 and 0.5 wt% CaF2), 
APS was used for functionalisation of the bioglass [127]. APS can bond to both bioglass and polylactide 
materials due to the presence of silanol groups which react with the bioglass, and amine groups which 
react with the carboxyl groups of hydrolysed PLLA to form hydrogen bonds. The use of APS to 
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functionalise the bioglass particles improved the bonding between the PLLA and bioglass particles 
which resulted in better incorporation of the bioglass particles into the PLLA matrix resulting in 
enhanced mechanical properties compared to non-functionalised samples [127]. In a different study, 
gelatin was functionalized with GPTMS and scaffolds with similar compression strength and modulus 
to cancellous bone were obtained [125]. Another interesting feature of these Class II hybrid scaffolds 
is that the apatite layer forms throughout the scaffold, whereas in purely  bioglass scaffolds (bioglass 
containing 75 wt% SiO2 and 25 wt% CaO) it was observed only on the surface [125]. 
Hexamethylene diisocyanate (HMDI) was used to functionalize PLLA to produce bonded 
PLLA/bioglass scaffolds (with bioglass composition: 58 wt% CaO, 29 wt% SiO2, 13 wt% P2O5) [126]. 
Even though the Young’s moduli of PLLA/bioglass scaffolds with or without HD were similar, higher 
tensile strength for the scaffold functionalized by diisocyanate was reported [126]. 
PVA/bioglass hybrid scaffolds (with bioglass composition: 58 wt% SiO2, 33 wt% CaO, 9 wt% 
P2O5) were fabricated by the sol-gel method with the addition of a surfactant followed by ageing and 
drying [128, 130]. The hydroxyl group of PVA and the hydroxyl group of silanol groups, originating 
from the hydrolysis of the silicon precursor tetraethyl orthosilicate (TEOS), have been shown to react 
with each other to form bonds (Figure 7) [128]. These PVA/bioglass scaffolds were considered as 
potential candidates for bone tissue applications, however, so far, no exceptional properties in 
comparison to other known polymer/bioglass scaffolds have been reported [128, 130]. 
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Figure 7: a) PVA with a variable hydrolysis degree and b) a hybrid structure reproduced from 
[128], available under a Creative Commons CC BY-NC (http://www.scielo.br/scielo.php?pid=S1516-
14392007000100006&script=sci_abstract) 
 
Lately, chitosan is drawing attention as a prospective component for Class II hybrid scaffolds 
with bioglasses. Glycidoxypropyltrimethoxysilane (GPTMS) was used for the functionalization of 
chitosan in order to form covalent bonds with bioglass via sol-gel synthesis [123]. Compared to 
chitosan and bioglass composites without GPTMS (Class l hybrids), specimens that were covalently 
bound (Class II hybrids) were less brittle. Figure 8 shows the functionalization of chitosan with GPTMS 
and formation of a chitosan/bioglass scaffold through the formation of a glass network thereby 
creating the hybrid. GPTMS is used as a cross-linking agent. 
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Figure 8: a) Functionalization of chitosan with GPTMS and b) formation of chitosan/bioglass hybrid 
scaffolds adapted with permission from [123]. Copyright 2015. Wiley Periodicals, Inc. 
 
Another way to form a Class II hybrid involving chitosan is using GPTMS while bioglass is not 
added in this procedure (unlike in the method described in Figure 8). The cross-links form by reaction 
of the epoxy group of GPTMS with the amine group of chitosan. At the same time, the methoxysilane 
groups undergo hydrolysis to silanol groups which then condense to form a siloxane network [124]. 
These SiOH groups bring bioactivity to the polymer. 
Further reports demonstrate PVA/chitosan/bioglass 60S (bioglass composition: 60.1 mol% 
SiO2, 17.7 mol% Na2O, 19.6 mol% CaO and 2.6% P2O5 mol%) hybrid scaffolds, fabricated with the 
addition of glutaraldehyde for cross-linking followed by freeze drying [129]. The untreated scaffolds 
showed toxicity, but after treatment with phosphate-buffered saline (PBS) cell viability increased. 
In general, both Class I and Class II hybrids containing chitosan and bioglass are attractive for 
regenerative medicine applications, as they combine the good properties of both materials and 
potentially match the composition, structure and properties of human hard and soft tissue (cartilage 
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and bone). Some of the hybrids (APS or HMDI functionalised bioglass/PLLA, GPTMS functionalised 
chitosan/bioglass, and GPTMS functionalised gelatine/bioglass) showed improved mechanical 
properties in comparison to composites without functionalisation, but they are still below the high 
load-bearing region. While some designs of bioglass/chitosan composite scaffolds have been 
described in the literature, there is a need for further studies to realise their full potential. So far, 
chitosan matrices with bioglass as a coating or with bioglass nanoparticles within the polymer matrix 
have been reported [4, 16, 25, 39-44, 75, 77, 78, 123]. These have shown suitable biological and 
mechanical properties in vitro such as bioactivity, cell adhesion, no cell toxicity, adequate swelling and 
degradation and compressive strength in the region of cancellous bone, making them good candidates 
for further trials [16, 25, 75, 77]. Nanocomposite chitosan/bioglass scaffolds (with bioglass 
composition: 60 mol% SiO2, 36 mol% CaO, 4 mol% P2O5) have  also been reported [78]. While they had 
the appropriate pore size for bone growth, insufficient mechanical strength was reported [78]. Other 
studies tested chitosan/bioglass scaffolds for drug delivery in vitro, but mechanical properties were 
either not reported or low [39-44]. On the whole, even in the case of Class II hybrid chitosan/bioglass 
scaffolds, in which covalent bonding improved properties, the mechanical properties remained in the 
region of low load-bearing applications [123]. 
5.2 Potential of chitosan based materials 
While drawing attention for use in hybrid scaffolds, chitosan is considered promising in the 
broader area of tissue engineering as it possesses a wide range of characteristics, such as non-toxicity, 
biocompatibility and biodegradability as well as having antibacterial properties while avoiding the 
problems linked to using collagen [25, 131]. Chitosan is a natural polycationic linear polysaccharide 
derived from chitin by deacetylation, although the process is never complete [131, 132]. Chitin is the 
second most abundant natural polysaccharide after cellulose and can be found in the exoskeletons of 
insects, shrimps, crabs, lobsters and in the cell walls of fungi [131]. As chitin is a waste material in the 
food industry, the production of chitosan is economically achievable and environmentally beneficial 
[132]. 
Chitosan has shown osteoconductive ability, as well as the ability to induce neovascularisation 
but shows very little osteoinductivity [131, 133]. One aspect to consider when using chitosan is its 
solubility, which is pH dependent (poor at neutral pH, and increasing as pH decreases) [133]. Chitosan 
on its own has insufficient mechanical strength and is easily degraded, especially in acidic 
surroundings, which can be an advantage for some in vivo applications but a drawback for others. It 
needs to be noted that chitosan can be unsuitable as blood-contacting material as it can cause 
thrombosis, aggregation of red blood cells and haemolysis [133]. 
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Chitosan has been successfully employed in hydrogels which are 3D polymer networks that 
have an affinity for water absorption due to the presence of hydrophilic groups. When in an aqueous 
environment, water infiltrates the hydrogel network and causes swelling, while electrostatic or 
covalent bonds present in the network stop its dissolution [134-136]. While there are a number of 
cross-linkers used for chitosan hydrogel preparation that react with chitosan’s amino groups 
(glutaraldehyde, formaldehyde, genipin, glyoxal, etc), these agents induce an increase in toxicity [134, 
137]. On that front, genipin, a natural compound that is derived from Gardenia jasminoides fruits 
shows promise [137-139]. The advantage of genipin over the other commonly used cross-linkers is 
significantly lower toxicity (10 000 times less than glutaraldehyde) being nontoxic at concentrations 
below 0.5 µM, while the gels produced maintain a slower degradation rate, the same mechanical 
properties and, as an added bonus, have an anti-inflammatory effect [134, 137, 140, 141]. Genipin-
cross-linked gels exhibit a 5 000 times higher cell proliferation rate and produce a reduced immune 
response in xenogenic matrices compared to gels cross-linked with glutaraldehyde [141, 142]. 
Currently, the significant drawback of using genipin is the high cost [139]. The reaction of genipin with 
chitosan, producing blue-coloured gels, is shown in Figure 9. It has been shown that variation in the 
quantity of genipin affects the structure and porosity of hydrogel networks [137, 143]. Genipin can 
self-polymerise, especially in a higher pH environment, which reduces the degree of cross-linking but 
introduces a further degree of freedom when it comes to pore geometry and size [139, 144]. By 
varying the reaction conditions, such as temperature or pH, the obtained genipin cross-linked chitosan 
can express different properties [145]. By increasing the temperature, denser and more cross-linked 
chitosan networks can be made [146]. Under variable pH conditions, different degrees of cross-linking 
can be obtained which can influence gel properties such as mechanical properties and the rate of drug 
release [147-149]. As mentioned previously, it is important to have the capacity to tailor porosity and 
structure of the material in order to gain desirable properties such as biocompatibility, controlled 
degradation with a controlled rate and suitable mechanical properties.  
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Figure 9: Possible genipin/chitosan cross-linking reactions adapted with permission from [150]. 
Copyright 2015. Wiley Periodicals, Inc. 
  
 
5. Conclusion 
Composite materials are pursued for bone tissue engineering as they resemble natural human bone 
consisting of organic and inorganic parts. The composite scaffolds reported so far are suitable for non-
load-bearing or low load-bearing applications, for example for biomolecule delivery, as bone defect 
fillers and for maxillofacial procedures. Currently, the materials in use have mechanical properties 
below or at the lower limit of human cortical bone. The weak point of the composites is the weak 
interfacial bonding between the polymer and bioglass phases which jeopardises the mechanical 
properties of the composite. 
One way to improve the bonding between the organic and inorganic phase of the composites is to 
introduce a covalent bond between the phases (formation of Class II hybrids). This results in a stronger 
interface, preferably enabling the two phases to degrade simultaneously. It is also important to choose 
the appropriate structures for developing scaffolds in order to achieve better mechanical properties, 
for example hydrogel coated ceramic scaffolds or microsphere scaffolds exhibit higher mechanical 
strength. 
As an alternative to collagen, using chitosan for developing scaffolds with bioglass will avoid problems 
such as allergy and pathogen transmission. Chitosan has suitable specific properties such as 
biocompatibility, biodegradability, antibacterial properties and it is abundant in nature. Introducing 
cross-linking agents to the polymers improves mechanical properties of the polymer phase. So far, 
only a few studies have reported the use of cross-linking agents (usually glutaraldehyde) in 
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polymer/bioglass, and specifically chitosan/bioglass, scaffolds. Given that improved synthesis 
methods will decrease the cost of genipin manufacturing, this cross-linking agent could be a major 
player in improving chitosan-based composite scaffolds with low toxicity. 
The literature suggests that combined methods need to be taken into account (new ways of forming 
covalent bond with novel coupling agents, cross-linking of polymer hydrogels, scaffold coating or 
multi-layered scaffolds) in order to develop appropriate scaffolds for high-load bearing implants. 
Replacement of collagen with other natural polymers, such as chitosan, should be considered. It 
should be emphasized that even when in vivo tests support the use of certain materials, clinical trials 
might show unexpected or inconclusive results and vary from patient to patient, which remains an 
issue. 
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